KCTD17

KCTD17 is a substrate-recognition adaptor for Cullin3-RING E3 ubiquitin ligase complexes (CRL3-KCTD17) that selects specific protein substrates for polyubiquitylation and proteasomal degradation, thereby controlling processes ranging from ciliogenesis to hepatic metabolism and tumorigenesis (PMID:25270598, PMID:28859855). Its BTB domain assembles into a closed pentamer that binds Cullin3 to form a 5:5 heterodecamer without a canonical 3-box motif, providing the structural scaffold for ligase assembly (PMID:28963344). Through this complex KCTD17 ubiquitylates a series of substrates: trichoplein at mother centrioles, whose degradation relieves Aurora-A activation and permits ciliogenesis to initiate downstream of Ndel1 (PMID:25270598, PMID:26880200); PHLPP2, whose glucagon/PKA-phosphorylation-dependent degradation prolongs Akt signaling to drive hepatic lipogenesis and steatosis (PMID:28859855); O-GlcNAcase (OGA), whose loss raises O-GlcNAcylation and stabilizes ChREBP to promote lipogenic gene expression in obesity (PMID:36402191); LZTR1, whose degradation stabilizes Ras and promotes hepatocellular carcinoma growth (PMID:39098817); Chop, whose degradation promotes adipogenic differentiation (PMID:36868076); and the transcription factor Zbtb7b, whose degradation lowers SERPINA3 and drives Par2/TGFβ-mediated stellate-cell activation and liver fibrosis (PMID:40744994). Independently of its adaptor role, KCTD17 also binds Gβγ through its C-terminal domain to blunt Gβγ-mediated sensitization of adenylyl cyclase 5, dampening GPCR-driven cAMP signaling (PMID:36736897).

1. 2014 High

   Established KCTD17 as a CRL3 substrate adaptor by showing it polyubiquitylates trichoplein at mother centrioles to license ciliogenesis, defining its core molecular activity.

   Evidence Global E3 ligase screen, reciprocal Co-IP, proteasome inhibition, non-ubiquitylatable trichoplein mutant, and siRNA knockdown with ciliogenesis readout

   PMID:25270598

   Open questions at the time

   • Substrate scope beyond trichoplein unknown at this stage
   • Structural basis of Cul3 engagement not defined
2. 2016 High

   Placed KCTD17 genetically downstream of Ndel1 in the trichoplein-Aurora A axis, resolving where in the ciliogenesis-suppression pathway it acts.

   Evidence siRNA co-knockdown epistasis and trichoplein rescue in cells plus Ndel1-hypomorphic mouse kidney epithelia

   PMID:26880200

   Open questions at the time

   • Does not address non-ciliary substrates
   • Regulation of KCTD17 activity in cycling cells unclear
3. 2017 High

   Defined the structural mechanism of complex assembly, showing the BTB domain forms a closed pentamer binding Cul3 as a 5:5 heterodecamer without a 3-box.

   Evidence X-ray crystallography of the BTB domain, SAXS, size-exclusion chromatography, and Cul3 binding assays

   PMID:28963344

   Open questions at the time

   • Substrate-binding determinants within the assembly not mapped
   • Full-length complex structure not solved
4. 2017 High

   Extended KCTD17 substrate range to metabolism by linking glucagon/PKA-phosphorylated PHLPP2 degradation to hepatic lipogenesis, revealing signal-dependent substrate recognition.

   Evidence MS identification of phospho-sites and interaction, Co-IP, shRNA knockdown in hepatocytes and obese mice, CRISPR PHLPP2-KO hepatoma cells

   PMID:28859855

   Open questions at the time

   • How phosphorylation creates the KCTD17 degron not structurally defined
   • Tissue specificity of this branch unaddressed
5. 2017 Medium

   Demonstrated functional conservation of the KCTD17-Cul3 module with Drosophila Insomniac, connecting the pathway to synaptic localization and sleep regulation.

   Evidence Transgenic rescue of inc mutant sleep phenotype by mammalian KCTDs, Cul3 interaction assays, neuronal localization imaging

   PMID:28558011

   Open questions at the time

   • No mammalian neuronal substrate identified
   • Redundancy with KCTD2/KCTD5 not separated
6. 2022 High

   Identified OGA as a KCTD17 substrate and a transcriptional feedback loop, showing Srebp1c-induced KCTD17 degrades OGA to stabilize ChREBP and drive steatosis.

   Evidence AAV-CRISPR hepatocyte-specific KO mice on HFD, CRISPR KO hepatoma cells, Kctd17/Oga double-KO epistasis, in vivo ASO knockdown, forced expression

   PMID:36402191

   Open questions at the time

   • Direct ubiquitylation sites on OGA not mapped
   • Crosstalk with the PHLPP2 branch in the same hepatocytes unresolved
7. 2023 Medium

   Revealed a non-adaptor function: the KCTD17 C-terminus binds Gβγ to suppress adenylyl cyclase 5 sensitization, dampening GPCR cAMP signaling distinct from CRL3 activity.

   Evidence Live-cell BRET, Co-IP, C-terminal truncation domain mapping, and AC5 cAMP sensitization assay

   PMID:36736897

   Open questions at the time

   • Whether Gβγ binding requires or competes with Cul3 assembly is unknown
   • Physiological GPCR contexts not defined
8. 2023 Medium

   Added Chop as a KCTD17-Cul3 substrate whose degradation promotes adipogenesis, expanding the metabolic substrate repertoire.

   Evidence Co-IP, gain/loss-of-function in preadipocytes with adipogenesis readouts, and ubiquitination assays

   PMID:36868076

   Open questions at the time

   • Mechanistic follow-up limited
   • Degron on Chop not characterized
9. 2023 Low

   Showed KCTD17 forms hetero-oligomers with KCTD5, raising the possibility of mixed BTB assemblies.

   Evidence Co-IP, live-cell BRET, and IP-luminescence domain mapping

   PMID:37762619

   Open questions at the time

   • No functional consequence of the KCTD5-KCTD17 heteromer established for KCTD17
   • Stoichiometry within the closed pentamer unknown
10. 2024 High

    Connected KCTD17 to oncogenesis by showing it degrades LZTR1 to stabilize Ras and promote hepatocellular carcinoma.

    Evidence Co-IP substrate identification, hepatocyte-specific KO mice with DEN-induced HCC, xenografts, and in vivo ASO treatment

    PMID:39098817

    Open questions at the time

    • Selectivity of KCTD17 for LZTR1 versus other Cul3 adaptors unclear
    • Human tumor genetic validation limited
11. 2024 Low

    Demonstrated partial redundancy among KCTD2/5/17 in HEK293 growth and GNB1 (Gβ1) regulation, contextualizing KCTD17 within an isoform family.

    Evidence Progressive CRISPR knockouts, cell growth assays, and transcriptome profiling

    PMID:38732215

    Open questions at the time

    • No KCTD17-specific molecular mechanism beyond Gβ1 regulation established
    • Whether Gβ1 is a degradation substrate or binding partner not resolved
12. 2025 Medium

    Identified Zbtb7b as a KCTD17 substrate linking it to liver fibrosis via SERPINA3 and Par2/TGFβ signaling, and validated pharmacological inhibition.

    Evidence KCTD17 depletion in dietary MASH mice, substrate identification, SERPINA3 correlation, and pharmacological inhibition reversing fibrosis in vivo

    PMID:40744994

    Open questions at the time

    • Direct ubiquitylation of Zbtb7b not biochemically reconstituted
    • Specificity of the inhibitor for KCTD17 not detailed

• How a single closed BTB pentamer achieves selective recognition of its diverse substrates—and how the adaptor and Gβγ-binding functions are coordinated within a cell—remains unresolved.
• No structure of KCTD17 bound to any substrate
• Determinants distinguishing substrate degradation from Gβγ sequestration unknown
• In vivo balance among competing substrates not established